Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,266 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $19,646.22. Following the sale, the general counsel now owns 33,510 shares of the company’s stock, valued at approximately $290,531.70. This represents a 6.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Stoke Therapeutics Stock Up 0.8 %

Shares of NASDAQ:STOK traded up $0.07 during trading on Thursday, reaching $8.33. The stock had a trading volume of 1,070,583 shares, compared to its average volume of 833,189. Stoke Therapeutics, Inc. has a 52 week low of $5.60 and a 52 week high of $17.58. The firm has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99. The stock has a fifty day simple moving average of $9.50 and a two-hundred day simple moving average of $11.51.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. On average, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics during the fourth quarter worth $63,000. Teacher Retirement System of Texas bought a new position in Stoke Therapeutics during the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. bought a new position in Stoke Therapeutics during the fourth quarter worth $124,000. Tower Research Capital LLC TRC increased its position in Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. bought a new position in Stoke Therapeutics during the fourth quarter worth $133,000.

Analyst Upgrades and Downgrades

STOK has been the subject of several research reports. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.